Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial

W. L. Peterson, D. Y. Graham, B. Marshall, M. J. Blaser, R. M. Genta, P. D. Klein, C. W. Stratton, J. Drnec, P. Prokocimer, N. Siepman

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

Current regimens to eradicate Helicobacter pylori usually consist of metronidazole plus a bismuth compound, as well as a third agent such as tetracycline. Such regimens are not ideal because organisms may be metronidazole-resistant, side-effects occur, and compliance is often poor. This randomized, double-blind study was designed to assess the ability of clarithromycin, a new macrolide antimicrobial, as monotherapy to eradicate H. pylori. Thirty-seven healthy volunteers who were H. pylori positive by 13C- urea breath test plus histology and/or culture completed 14 days of oral therapy with clarithromycin in one of three dosages. Eradication, defined as all three tests negative at 4-6 wk after the end of therapy, was achieved in 2/13 (15%) with clarithromycin 500 mg bid, 4/11 (36%) with 1000 mg bid, and 7/13 (54%) with 500 mg qid. Isolates of H. pylori were resistant to clarithromycin prior to therapy in 12% of subjects, and became resistant during therapy in 21% of subjects. Taste perversion, the most common side effect, resulted in one subject terminating therapy. Conclusions: Whereas clarithromycin is a promising antimicrobial in the eradication of H. pylori, it is not sufficient to be used as monotherapy.

Original languageEnglish (US)
Pages (from-to)1860-1864
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume88
Issue number11
StatePublished - 1993

Fingerprint

Clarithromycin
Helicobacter pylori
Metronidazole
Therapeutics
Bismuth
Breath Tests
Aptitude
Macrolides
Tetracycline
Double-Blind Method
Compliance
Urea
Histology
Healthy Volunteers

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Peterson, W. L., Graham, D. Y., Marshall, B., Blaser, M. J., Genta, R. M., Klein, P. D., ... Siepman, N. (1993). Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. American Journal of Gastroenterology, 88(11), 1860-1864.

Clarithromycin as monotherapy for eradication of Helicobacter pylori : A randomized, double-blind trial. / Peterson, W. L.; Graham, D. Y.; Marshall, B.; Blaser, M. J.; Genta, R. M.; Klein, P. D.; Stratton, C. W.; Drnec, J.; Prokocimer, P.; Siepman, N.

In: American Journal of Gastroenterology, Vol. 88, No. 11, 1993, p. 1860-1864.

Research output: Contribution to journalArticle

Peterson, WL, Graham, DY, Marshall, B, Blaser, MJ, Genta, RM, Klein, PD, Stratton, CW, Drnec, J, Prokocimer, P & Siepman, N 1993, 'Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial', American Journal of Gastroenterology, vol. 88, no. 11, pp. 1860-1864.
Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. American Journal of Gastroenterology. 1993;88(11):1860-1864.
Peterson, W. L. ; Graham, D. Y. ; Marshall, B. ; Blaser, M. J. ; Genta, R. M. ; Klein, P. D. ; Stratton, C. W. ; Drnec, J. ; Prokocimer, P. ; Siepman, N. / Clarithromycin as monotherapy for eradication of Helicobacter pylori : A randomized, double-blind trial. In: American Journal of Gastroenterology. 1993 ; Vol. 88, No. 11. pp. 1860-1864.
@article{a3500f5095c94ba3aeec53afefabeee5,
title = "Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial",
abstract = "Current regimens to eradicate Helicobacter pylori usually consist of metronidazole plus a bismuth compound, as well as a third agent such as tetracycline. Such regimens are not ideal because organisms may be metronidazole-resistant, side-effects occur, and compliance is often poor. This randomized, double-blind study was designed to assess the ability of clarithromycin, a new macrolide antimicrobial, as monotherapy to eradicate H. pylori. Thirty-seven healthy volunteers who were H. pylori positive by 13C- urea breath test plus histology and/or culture completed 14 days of oral therapy with clarithromycin in one of three dosages. Eradication, defined as all three tests negative at 4-6 wk after the end of therapy, was achieved in 2/13 (15{\%}) with clarithromycin 500 mg bid, 4/11 (36{\%}) with 1000 mg bid, and 7/13 (54{\%}) with 500 mg qid. Isolates of H. pylori were resistant to clarithromycin prior to therapy in 12{\%} of subjects, and became resistant during therapy in 21{\%} of subjects. Taste perversion, the most common side effect, resulted in one subject terminating therapy. Conclusions: Whereas clarithromycin is a promising antimicrobial in the eradication of H. pylori, it is not sufficient to be used as monotherapy.",
author = "Peterson, {W. L.} and Graham, {D. Y.} and B. Marshall and Blaser, {M. J.} and Genta, {R. M.} and Klein, {P. D.} and Stratton, {C. W.} and J. Drnec and P. Prokocimer and N. Siepman",
year = "1993",
language = "English (US)",
volume = "88",
pages = "1860--1864",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Clarithromycin as monotherapy for eradication of Helicobacter pylori

T2 - A randomized, double-blind trial

AU - Peterson, W. L.

AU - Graham, D. Y.

AU - Marshall, B.

AU - Blaser, M. J.

AU - Genta, R. M.

AU - Klein, P. D.

AU - Stratton, C. W.

AU - Drnec, J.

AU - Prokocimer, P.

AU - Siepman, N.

PY - 1993

Y1 - 1993

N2 - Current regimens to eradicate Helicobacter pylori usually consist of metronidazole plus a bismuth compound, as well as a third agent such as tetracycline. Such regimens are not ideal because organisms may be metronidazole-resistant, side-effects occur, and compliance is often poor. This randomized, double-blind study was designed to assess the ability of clarithromycin, a new macrolide antimicrobial, as monotherapy to eradicate H. pylori. Thirty-seven healthy volunteers who were H. pylori positive by 13C- urea breath test plus histology and/or culture completed 14 days of oral therapy with clarithromycin in one of three dosages. Eradication, defined as all three tests negative at 4-6 wk after the end of therapy, was achieved in 2/13 (15%) with clarithromycin 500 mg bid, 4/11 (36%) with 1000 mg bid, and 7/13 (54%) with 500 mg qid. Isolates of H. pylori were resistant to clarithromycin prior to therapy in 12% of subjects, and became resistant during therapy in 21% of subjects. Taste perversion, the most common side effect, resulted in one subject terminating therapy. Conclusions: Whereas clarithromycin is a promising antimicrobial in the eradication of H. pylori, it is not sufficient to be used as monotherapy.

AB - Current regimens to eradicate Helicobacter pylori usually consist of metronidazole plus a bismuth compound, as well as a third agent such as tetracycline. Such regimens are not ideal because organisms may be metronidazole-resistant, side-effects occur, and compliance is often poor. This randomized, double-blind study was designed to assess the ability of clarithromycin, a new macrolide antimicrobial, as monotherapy to eradicate H. pylori. Thirty-seven healthy volunteers who were H. pylori positive by 13C- urea breath test plus histology and/or culture completed 14 days of oral therapy with clarithromycin in one of three dosages. Eradication, defined as all three tests negative at 4-6 wk after the end of therapy, was achieved in 2/13 (15%) with clarithromycin 500 mg bid, 4/11 (36%) with 1000 mg bid, and 7/13 (54%) with 500 mg qid. Isolates of H. pylori were resistant to clarithromycin prior to therapy in 12% of subjects, and became resistant during therapy in 21% of subjects. Taste perversion, the most common side effect, resulted in one subject terminating therapy. Conclusions: Whereas clarithromycin is a promising antimicrobial in the eradication of H. pylori, it is not sufficient to be used as monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027358581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027358581&partnerID=8YFLogxK

M3 - Article

C2 - 8237933

AN - SCOPUS:0027358581

VL - 88

SP - 1860

EP - 1864

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 11

ER -